Publication Date

10-2019

Files

Download

Download Full Text (717 KB)

Abstract

Background: Intravenous immune globulin (IVIG) is a plasma-derived product from pooled donors. It has six FDA approved indications. It is also considered standard of care for a few other conditions in specific populations. Additionally, there is growing non-evidence-based use. Due to a global shortage, IVIG has become increasing difficult to obtain.

. . . .

Conclusions: Development, implementation, and promotion of adherence to an evidence-based criterion allowed our scarce IVIG supply to be sustained. Further refinement of the criteria for use is ongoing, as is an evaluation of IVIG utilization by indication, pre- and post-implementation. This process can be applied to other situations of scarce resources

MeSH Keywords

Immunoglobulins, Intravenous; Evidence-Based Practice; Resource Allocation; Quality Improvement

Keywords

IVIG

Disciplines

Health and Medical Administration | Pharmacy and Pharmaceutical Sciences

Collection

National Healthcare Quality Week

Development and Implementation of an Evidence-Based Process for Scarce Resource Allocation

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.